respiratory, dermatology, and cancer. AstraZeneca is a multinational, science-driven biopharmaceutical business specialized in the discovery, manufacture, and marketing of prescription medications in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal, and metabolism, as well as respiratory and immunology.
Under the terms of the agreement, AstraZeneca will retain registration for Pulmicort Respules® and will manufacture the medicine and Glenmark will be responsible for the product’s marketing in Colombia. This collaboration will assure sustained and enhanced access to this critical medicine, providing the required therapeutic solution to Colombian asthma patients.
Glenmark Pharmaceuticals, a multinational pharmaceutical business that is focused on innovative medication announced that its subsidiary Glenmark Pharmaceuticals Colombia S.A.S. has reached an exclusive licensing agreement with AstraZeneca Colombia S.A.S. for the marketing of AstraZeneca’s medication Pulmicort Respules®. As part of the deal, AstraZeneca will retain registration for Pulmicort Respules® and will be in charge of producing and delivering the medicine; while, Glenmark will be in charge of marketing of Pulmicort Respules® in Colombia.
Mr. Marco Cerato, Executive Vice President and Global Head – Business Development of Glenmark Pharmaceuticals, expressed delight over the partnership with AstraZeneca. He said, “We are excited to collaborate with AstraZeneca and ensure continued and increased access of Pulmicort Respules®, a high quality essential therapy to Colombian patients suffering from bronchial asthma. It will also help us in strengthening our key therapy area of respiratory medicine in the region.”
Glemont L (Montelukast + Levocetorizine), Glencet; Levocetirizine, Furomet (Mometasone NS), Complebrez (Formoterol + Budesonide), and Sibet (Salmeterol + Fluticasone) are Glenmark’s existing respiratory portfolio now available in Latin America. The collaboration between Glenmark and AstraZeneca will assure continuing and expanded access to this critical medicine, bringing essential therapeutic respite to Colombian asthma sufferers.
